专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070105909A1 Compounds useful in therapy 失效
标题翻译：化合物可用于治疗
公开(公告)号：US20070105909A1
公开(公告)日：2007-05-10
申请号：US11592574
申请日：2006-11-03
申请人： Paul Bradley , Kevin Dack , Patrick Johnson , Sarah Skerratt
发明人： Paul Bradley , Kevin Dack , Patrick Johnson , Sarah Skerratt
IPC分类号： A61K31/4439 , A61K31/4152 , C07D403/02 , C07D231/12
CPC分类号： C07D231/18 , C07D401/12
摘要： Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein R1 and R3 independently represent H, C1-6alkyl, C3-8cycloalkyl, or halogen; R2 represents C1-6alkyl, CF3 or aryl; a represents 1 or 2; R4, R5, R7 and R8 independently represent H, C1-6alkyl, C1-6alkyloxy, CN or halogen, or R4 and R5, or R7 and R8, together with the ring to which they are attached form an aryl or heterocyclic fused ring system; X represents C or N; Y represents CH2 or O; R6 represents H, CN or halo provided that, when X represents N, R6 is absent. The compounds are useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
摘要翻译：式（I）化合物或其药学上可接受的衍生物，其中R 1和R 3独立代表H，C 1-6烷基 C 3-8环烷基或卤素; R 2表示C 1-6烷基，CF 3或芳基; a代表1或2; R 4，R 5，R 7和R 8独立地表示H，C 1-6 C 1-6烷基，C 1-6烷氧基，CN或卤素，或R 4和R 5或R 7 和它们所连接的环连接形成芳基或杂环稠环体系; X表示C或N; Y表示CH 2或O; R 6表示H，CN或卤素，条件是当X表示N时，R 6不存在。这些化合物可用于治疗子宫内膜异位症，子宫肌瘤（平滑肌瘤），月经过多，子宫腺肌症，原发性和继发性痛经（包括性交疼痛，dyschexia和慢性盆腔疼痛症状）或慢性盆腔疼痛综合征。

2. 发明申请

US20080085919A1 1H-Pyrazoles Useful In Therapy 失效
标题翻译： 1H-吡唑有用的治疗
公开(公告)号：US20080085919A1
公开(公告)日：2008-04-10
申请号：US11870451
申请日：2007-10-11
申请人： Paul Bradley , Kevin Dack , Patrick Johnson , Sarah Skerratt
发明人： Paul Bradley , Kevin Dack , Patrick Johnson , Sarah Skerratt
IPC分类号： A61K31/415 , A61K31/4152 , A61K31/4709 , A61P43/00 , A61P7/00
CPC分类号： C07D231/18 , C07D401/12
摘要： Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein R1 and R3 independently represent H, C1-6alkyl, C3-8cycloalkyl, or halogen; R2 represents C1-6alkyl, CF3 or aryl; a represents 1 or 2; R4, R5, R7 and R8 independently represent H, C1-6alkyl, C1-6alkyloxy, CN or halogen, or R4 and R5, or R7 and R8, together with the ring to which they are attached form an aryl or heterocyclic fused ring system; X represents C or N; Y represents CH2 or O; R6 represents H, CN or halo provided that, when X represents N, R6 is absent. The compounds are useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
摘要翻译：式（I）化合物或其药学上可接受的衍生物，其中R 1和R 3独立代表H，C 1-6烷基 C 3-8环烷基或卤素; R 2表示C 1-6烷基，CF 3或芳基; a代表1或2; R 4，R 5，R 7和R 8独立地表示H，C 1-6 C 1-6烷基，C 1-6烷氧基，CN或卤素，或R 4和R 5或R 7 和它们所连接的环连接形成芳基或杂环稠环体系; X表示C或N; Y表示CH 2或O; R 6表示H，CN或卤素，条件是当X表示N时，R 6不存在。这些化合物可用于治疗子宫内膜异位症，子宫肌瘤（平滑肌瘤），月经过多，子宫腺肌症，原发性和继发性痛经（包括性交疼痛，dyschexia和慢性盆腔疼痛症状）或慢性盆腔疼痛综合征。

3. 发明申请

US20060241125A1 Compounds useful in therapy 失效
标题翻译：化合物可用于治疗
公开(公告)号：US20060241125A1
公开(公告)日：2006-10-26
申请号：US11408286
申请日：2006-04-18
申请人： Paul Bradley , Kevin Dack , Ian Marsh
发明人： Paul Bradley , Kevin Dack , Ian Marsh
IPC分类号： A61K31/506 , A61K31/4152 , C07D403/02
CPC分类号： C07D231/28 , C07D231/18 , C07D401/04 , C07D401/06 , C07D403/04 , C07D403/06 , C07D413/06 , C07D417/06
摘要： Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: R1 represents H, C1-6-alkyl, C1-6alkyloxy, C3-8cycloalkyl, or halo; R2 represents H, C1-6alkyl (optionally substituted by R3), phenyl (optionally substituted by CN), or Het; R3 represents OH, CN, Het, —R4—C1-6alkyl, or CONR5R6; R4 represents —CO2—, or —O—; R5 and R6 independently represent H, C1-6alkyl (optionally substituted by OR7) or C3-8cycloalkyl; R7 represents H or C1-6alkyl; Het represents a five or six membered aromatic heterocyclic group containing (i) from one to four nitrogen heteroatom(s) or (ii) one or two nitrogen heteroatom(s) and one oxygen or one sulphur heteroatom or (iii) one or two oxygen or sulphur heteroatom(s), said heterocyclic group being optionally substituted by one or more groups selected from CN and C1-6 alkyl; R8 represents C1-6alkyl, C1-6alkyloxy, C3-8cycloalkyl, or halo; R9 and R10 independently represent H, C1-6alkyl, C1-6alkyloxy, CN, CF3 or halo; may be useful for treating endometriosis, uterine fibroids (leiomyomata), menorrhagia, adenomyosis, primary and secondary dysmenorrhoea (including symptoms of dyspareunia, dyschexia and chronic pelvic pain), or chronic pelvic pain syndrome.
摘要翻译：式（I）化合物或其药学上可接受的衍生物，其中：R 1表示H，C 1-6烷基，C 1-6烷基，烷氧基，C 3-8环烷基或卤素; R 2表示H，C 1-6烷基（任选被R 3 O 3取代），苯基（任选被CN取代）或Het; R 3表示OH，CN，Het，-R 4 -C 1-6烷基或CONR 5 R 6; R 4表示-CO 2 - 或-O-; R 5和R 6独立地表示H，C 1-6烷基（任选被OR 7取代）或 C 3-8环烷基; R 7表示H或C 1-6烷基; Het表示含有（i）1-4个氮杂原子或（ii）一个或两个氮杂原子和一个氧或一个硫杂原子的五元或六元芳族杂环基，或（iii）一个或两个氧或硫杂原子，所述杂环基团任选被一个或多个选自CN和C 1-6烷基的基团取代; R 8表示C 1-6烷基，C 1-6烷氧基，C 3-8环烷基，或光环; R 9和R 10独立地代表H，C 1-6烷基，C 1-6烷氧基，CN CF 3或卤素; 可能有助于治疗子宫内膜异位症，子宫肌瘤（平滑肌瘤），月经过多，子宫腺肌症，原发性和继发性痛经（包括性交疼痛，dyschexia和慢性盆腔疼痛症状）或慢性盆腔疼痛综合征。

4. 发明申请

US20090247539A1 Novel Pharmaceuticals 有权
标题翻译：新药
公开(公告)号：US20090247539A1
公开(公告)日：2009-10-01
申请号：US12481939
申请日：2009-06-10
申请人： Andrew Simon Bell , David Graham Brown , Kevin Dack , David Nathan Abraham Fox , Ian Roger Marsh , Andrew Ian Morrell , Michael John Palmer , Carol Ann Winslow
发明人： Andrew Simon Bell , David Graham Brown , Kevin Dack , David Nathan Abraham Fox , Ian Roger Marsh , Andrew Ian Morrell , Michael John Palmer , Carol Ann Winslow
IPC分类号： A61K31/519 , C07D487/04 , A61P9/12
CPC分类号： C07D487/04
摘要： This invention relates to compounds of formula (I)
摘要翻译：本发明涉及式（I）化合物，

5. 发明授权

US08097621B2 Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors 有权
标题翻译：吡唑并[4,3-d]嘧啶，为磷酸二酯酶抑制剂
公开(公告)号：US08097621B2
公开(公告)日：2012-01-17
申请号：US12481939
申请日：2009-06-10
申请人： Andrew Simon Bell , David Graham Brown , Kevin Dack , David Nathan Abraham Fox , Ian Roger Marsh , Andrew Ian Morrell , Michael John Palmer , Carol Ann Winslow
发明人： Andrew Simon Bell , David Graham Brown , Kevin Dack , David Nathan Abraham Fox , Ian Roger Marsh , Andrew Ian Morrell , Michael John Palmer , Carol Ann Winslow
IPC分类号： C07D487/04 , A61K31/519 , A61P9/12 , A61P25/28 , A61P11/06 , A61P15/10
CPC分类号： C07D487/04
摘要： This invention relates to compounds of formula (I)
摘要翻译：本发明涉及式（I）化合物，

6. 发明授权

US07572799B2 Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors 有权
标题翻译：吡唑并[4,3-d]嘧啶作为磷酸二酯酶抑制剂
公开(公告)号：US07572799B2
公开(公告)日：2009-08-11
申请号：US10997191
申请日：2004-11-24
申请人： Andrew Simon Bell , David Graham Brown , Kevin Dack , David Nathan Abraham Fox , Ian Roger Marsh , Andrew Ian Morrell , Michael John Palmer , Carol Ann Winslow
发明人： Andrew Simon Bell , David Graham Brown , Kevin Dack , David Nathan Abraham Fox , Ian Roger Marsh , Andrew Ian Morrell , Michael John Palmer , Carol Ann Winslow
IPC分类号： C07D487/04 , A61K31/519 , A61P9/12 , A61P25/28 , A61P11/06 , A61P3/04 , A61P9/10 , A61P35/04 , A61P25/02
CPC分类号： C07D487/04
摘要： This invention relates to compounds of formula (I)
摘要翻译：本发明涉及式（I）化合物，

7. 发明申请

US20050026836A1 Composition for the treatment of damaged tissue 审中-公开
标题翻译：用于治疗受损组织的组合物
公开(公告)号：US20050026836A1
公开(公告)日：2005-02-03
申请号：US10901417
申请日：2004-07-28
申请人： Kevin Dack , Michael Davies , Paul Fish , Jonathan Huggins , Fraser McIntosh , Nicholas Occleston
发明人： Kevin Dack , Michael Davies , Paul Fish , Jonathan Huggins , Fraser McIntosh , Nicholas Occleston
IPC分类号： A61K38/18 , A61K38/48 , A61K38/49 , A61K38/55 , A61K45/06 , B41J2/175 , B41J2/19
CPC分类号： B41J2/17513 , A61K45/06 , B41J2/17503 , B41J2/19
摘要： A pharmaceutical for use in damaged tissue, such as wound, treatment (e.g. healing) is described. The pharmaceutical comprising a composition which comprises: (a) a growth factor; and (b) an inhibitor agent; and optionally (c) a pharmaceutically acceptable carrier, diluent or excipient; wherein the inhibitor agent can inhibit the action of at least one specific adverse protein (e.g. a specific protease) that is upregulated in a damaged tissue, such as a wound, environment.
摘要翻译：描述了用于损伤组织例如伤口，治疗（例如愈合）的药物。该药物包含组合物，其包含：（a）生长因子; 和（b）抑制剂; 和（c）药学上可接受的载体，稀释剂或赋形剂; 其中所述抑制剂可以抑制在受损组织例如伤口环境中上调的至少一种特异性不利蛋白（例如特定蛋白酶）的作用。

8. 发明申请

US20050245544A1 Novel pharmaceuticals 有权
公开(公告)号：US20050245544A1
公开(公告)日：2005-11-03
申请号：US10997191
申请日：2004-11-24
申请人： Andrew Bell , David Brown , Kevin Dack , David Fox , Ian Marsh , Andrew Morrell , Michael Palmer , Carol Winslow
发明人： Andrew Bell , David Brown , Kevin Dack , David Fox , Ian Marsh , Andrew Morrell , Michael Palmer , Carol Winslow
IPC分类号： A61K31/519 , C07D487/02 , C07D487/04
CPC分类号： C07D487/04
摘要： This invention relates to compounds of formula (I)

9. 发明申请

US20050075392A1 Novel pharmaceuticals 失效
标题翻译：新药
公开(公告)号：US20050075392A1
公开(公告)日：2005-04-07
申请号：US10739425
申请日：2003-12-18
申请人： Kevin Dack , Robert Maguire
发明人： Kevin Dack , Robert Maguire
IPC分类号： C07D213/30 , C07D295/185 , A61K31/215
CPC分类号： C07D213/30 , C07D295/185
摘要： The invention relates to NEP inhibitors for treating cardiovascular disorders. Preferred NEP inhibitors are compounds of formula (I) wherein R1 is C1-C6alkyl, C1-C6alkoxyC1-C3alkyl or C1-C6alkoxyC1-C6alkoxyC1-C3alkyl; R2 is hydrogen or C1-C6alkyl; L is a three atom linkage selected from —CH2—X—CH2— and —CH2—CH2—X— where the right hand side of the linkage is attached to R3 and where X is oxygen, sulfur or methylene; R3 is phenyl or aromatic heterocyclyl, either of which may be independently substituted by one or more groups selected from: C1-C6alkyl, halo, haloC1-C6alkyl, C1-C6alkoxy, haloC1-C6alkoxy, C1-C6alkylthio, haloC1-C6alkylthio and nitrile; and R4 and R5 are either both hydrogen, or one of R4 and R5 is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen.
摘要翻译：本发明涉及用于治疗心血管疾病的NEP抑制剂。优选的NEP抑制剂是式（I）的化合物，其中R 1是C 1 -C 6烷基，C 1 -C 6烷氧基C 1 -C 3烷基或C 1 -C 6烷氧基C 1 -C 6烷氧基C 1 -C 3烷基; R 2是氢或C 1 -C 6烷基; L是选自-CH 2 -X-CH 2 - 和-CH 2 -CH 2 -X-的三原子键，其中键的右手侧连接到R 3，其中X是氧，硫或亚甲基; R 3是苯基或芳族杂环基，其中任一个可以独立地被一个或多个选自以下的基团取代：C 1 -C 6烷基，卤素，卤代C 1 -C 6烷基，C 1 -C 6烷氧基，卤代C 1 -C 6烷氧基，C 1 -C 6烷硫基，卤代C 1 -C 6烷硫基和腈; R 4和R 5都是氢，R 4和R 5中的一个是氢，另一个是生物不稳定酯形成基团，在患者体内被氢替代。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式